Connect Biopharma Holdings Ltd - Asset Resilience Ratio
Connect Biopharma Holdings Ltd (CNTB) has an Asset Resilience Ratio of 0.00% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2018–2025)
This chart shows how Connect Biopharma Holdings Ltd's Asset Resilience Ratio has changed over time. Check CNTB strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Connect Biopharma Holdings Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Connect Biopharma Holdings Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Connect Biopharma Holdings Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Connect Biopharma Holdings Ltd Industry Peers by Asset Resilience Ratio
Compare Connect Biopharma Holdings Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Connect Biopharma Holdings Ltd (2018–2025)
The table below shows the annual Asset Resilience Ratio data for Connect Biopharma Holdings Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 10.69% | $6.00 Million | $56.08 Million | -4.59pp |
| 2024-12-31 | 15.28% | $15.48 Million | $101.28 Million | +5.36pp |
| 2023-12-31 | 9.92% | $12.64 Million | $127.38 Million | -32.26pp |
| 2022-12-31 | 42.18% | $73.41 Million | $174.01 Million | +42.18pp |
| 2021-12-31 | 0.00% | $677.10 | $291.05 Million | -1.20pp |
| 2020-12-31 | 1.20% | $306.41K | $25.44 Million | -7.02pp |
| 2019-12-31 | 8.22% | $635.15K | $7.73 Million | +7.69pp |
| 2018-12-31 | 0.54% | $371.01K | $69.29 Million | -- |
About Connect Biopharma Holdings Ltd
Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.